Fisher and Paykel Healthcare Reusable Breathing Circuit: Class I Recall – Pinholes in Tubes
FDA notified healthcare professionals that the Fisher & Paykel Healthcare Reusable Breathing Circuit, Model 900MR068, was recalled due to pinholes in the tubes used in the reusable breathing circuit. If these pinholes are not detected during the standard leak test before patient use, it could potentially result in a gas leak in the breathing system, which may lead to a loss of pressure for the intended ventilation therapy. Usage of the defective device may result in patient death. More information
Medication Guides for Certain Prescription Medicines
The FDA wants you to know the importance of reading Medication Guides—paper handouts that come with many prescription medicines. “The information in a Medication Guide is very important when it comes to getting the most benefit for your health from a medicine,” says Paul Seligman, M.D., M.P.H., former Associate Director for Safety Policy and Communication in FDA’s Center for Drug Evaluation and Research. “These guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events. To continue reading this Consumer Update or for more information about currently FDA approved Medication Guides.
Comunicaciones de la FDA sobre la seguridad de los medicamentos en español
Descargo de responsabilidad: La FDA reconoce la necesidad de proporcionar información sobre seguridad importante en idiomas distintos al inglés. Hacemos lo mejor posible para proporcionar versiones en español precisas y oportunas de nuestras Comunicaciones de Seguridad de Medicamentos. Sin embargo, en caso que existiera discrepancias entre las versiones en ingles y en español, la información contenida en la versión en inglés es la que se considera como versión oficial. Si tiene alguna pregunta, por favor contáctese con Division of Drug Information en druginfo@fda.hhs.gov. Comunicaciones de la FDA
For more important safety information on human drug and devices or to report a serious problem, please visit MedWatch.
FDA recognizes the significant public health consequences that can result from drug shortages and takes tremendous efforts within its legal authority to address and prevent drug shortages. These shortages occur for many reasons, including manufacturing and quality problems, delays, and discontinuations. When quality/manufacturing and quality problems, delays, and discontinuations. When quality/manufacturing issues are discovered by the company or the public and reported to FDA or are found by FDA upon inspection, the FDA works closely with the firm to address risks involved to prevent harm to patients. FDA also considers the impact a shortage would have on patient care and access and works with the firm to restore supplies while also ensuring safety for patients. More information
Drug Shortages Voluntarily Reported by Manufacturers During the Past 2 Weeks:
No current shortages reported
Drug Shortages Resolved During the Past 2 Weeks:
No current shortages resolved
Drugs to be Discontinued Announced During Past 2 Weeks:
Eliquis approved to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation
FDA approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. More information
Sirturo approved to treat multi-drug resistant pulmonary tuberculosis
FDA approved Sirturo (bedaquiline) as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available. TB is an infection caused by Mycobacterium tuberculosis and is one of the world’s deadliest diseases. It is spread from person to person through the air and usually affects the lungs, but it can also affect other parts of the body such as the brain and kidneys. More information
Fulyzag approved as first anti-diarrheal drug for HIV/AIDS patients
FDA approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. More information
For information on drug approvals or to view prescribing information and patient information, please visit Drugs@FDA or DailyMed.
Guidance Documents on MDUFA III
The Food and Drug Administration Safety and Innovation Act (Public Law 112-144) includes the Medical Device User Fee Amendments of 2012, or MDUFA III. MDUFA III will take effect on October 1, 2012 and will sunset in five years on October 1, 2017. Device user fees were first established by Congress in 2002. Medical device companies pay fees to FDA when they register their establishment and list their devices with the agency, whenever they submit an application or a notification to market a new medical device in the U.S. and for certain other types of submissions. The FDA are issuing a series of guidance documents that help explain key provisions of MDUFA III. These guidance documents include 3 new guidance’s dated December 31, 2012.
Request for Comments: Framework for Pharmacy Compounding – State and Federal Roles
FDA is soliciting either comments on the issues discussed in section II of this document. Comments are due by January 18, 2013. More information
Request for Comments: Custom Devices
FDA is in the process of developing an implementation strategy and policy for the custom device exemption criteria in the FD&C Act amended by FDASIA. FDA is seeking information on appropriate uses of the custom device exemption. FDA is seeking information on and examples of appropriate uses of the custom device exemption identified in section 520(b) of the FD&C Act. FDA encourages all stakeholders, including patients, physicians, dentists, and manufacturers, to submit comments on the appropriate use of this statutory provision. Comments are due by January 18, 2013. More information
Request for Comments: Draft Guidance for Industry – Electronic Source Data in Clinical Investigations
FDA is announcing the availability of a draft guidance for industry entitled “Electronic Source Data in Clinical Investigations.” This document revises and updates the draft guidance entitled “Electronic Source Documentation in Clinical Investigations.” This revised draft document provides guidance to sponsors, CROs, data management centers, clinical investigators, and others involved in capturing, reviewing, and archiving electronic source data in FDA-regulated clinical investigations. The revised draft guidance promotes capturing source data in electronic form, and it is intended to assist in ensuring the reliability, quality, integrity, and traceability of electronic source data. Comments are due by January 22, 2013. More information
Request for Comments: Draft Guidance for IRBs, Clinical Investigators, and Sponsors – IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE Is Needed
This draft guidance announced in this notice is intended to assist institutional review boards (IRBs), clinical investigators, and sponsors involved in clinical investigations of FDA-regulated products in fulfilling responsibilities related to reviewing the qualifications of investigators, adequacy of research sites, and the determination of whether an investigational new drug (IND) application or investigational device exemption (IDE) is needed in order to assure the protection of the rights and welfare of human subjects in clinical investigations. Comments are due by January 22, 2013. More information
Draft Guidances for Industry: Safety Considerations for Product Design to Minimize Medication Errors
This draft guidance provides sponsors of investigational new drug applications, new drug applications, biologics licensing applications, abbreviated new drug applications, and nonprescription drugs marketed without an approved application (e.g., monograph) with a set of principles for developing drug products using a systems approach to minimize medication errors relating to product design. The draft guidance includes recommendations intended to improve the drug product and container closure design at the earliest stages of product development for all prescription and nonprescription drug products. Comments are due by February 11, 2013. More information
Request for Comments and Information on Initiating a Risk Assessment for Establishing Food Allergen Thresholds
Food allergy is an immune-mediated sensitivity to foods that can lead to life-threatening adverse reactions. Because there is no cure for food allergy, allergic consumers must use avoidance to prevent allergic reactions. Successful avoidance requires, among other things, that allergic consumers and their caregivers be able to read and understand the ingredient lists on packaged foods. Comments are due by February 12, 2013. More information
Request for Comments: Draft Guidance for Industry on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products
FDA is announcing the availability of a draft guidance for industry entitled “Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products.” This document provides guidance to industry on enrichment strategies that can be used in clinical trials intended to support effectiveness and safety claims in new drug applications (NDAs) and biologics license applications (BLAs). Comments due by February 15, 2013. More information
Request for Comments: Information To Accompany Humanitarian Device Exemption Applications and Annual Distribution Number Reporting Requirements
FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Comments are due by February 15, 2013. More information
Request for Comments Date Extended: Information on Nicotine Replacement Therapies and Smoking-Cessation Products
FDA is extending the comment period for the notice of public hearing that appeared in the Federal Register of November 28, 2012 (77 FR 70955). In the public hearing notice, FDA requested comments on FDA consideration of applicable approval mechanisms and additional indications for nicotine replacement therapies (NRTs), and input on a report to Congress examining the regulation and development of innovative products and treatments for tobacco dependence. The Agency is taking this action to allow interested persons additional time to submit comments. More information
Request for Comments: Draft Guidance for Industry – Development of Vaginal Microbicides for the Prevention of Human Immunodeficiency Virus Infection
FDA is announcing the availability of a draft guidance for industry entitled ‘‘Vaginal Microbicides: Development for the Prevention of HIV Infection.’’ The purpose of this guidance is to assist sponsors in all phases of development of vaginal microbicides for the prevention of human immunodeficiency virus (HIV) infection. The guidance outlines the types of nonclinical studies and clinical trials recommended throughout the drug development process to support approval of vaginal microbicides.Comments are due by February 21, 2013. More information
Request for Comments: Clinical Development Programs for Disease-Modifying Agents for Peripheral Neuropathy and Public Workshop
FDA will be holding an open public hearing and workshop to further the understanding of the development of disease-modifying agents for the treatment of painful peripheral neuropathies. Discussion will focus on possible therapeutic targets for these agents, the types of painful peripheral neuropathies amenable to treatment with disease-modifying agents, and clinical trial design. To attend workshop, registration is required by February 1, 2013. Comments are due by March 11, 2013.More information
Request for Comments: Draft Guidance for Industry and FDA Staff – Design Considerations for Devices Intended for Home Use
FDA is announcing the availability of the draft guidance entitled “Design Considerations for Devices Intended for Home Use.” This document is intended to assist manufacturers in designing and developing home use medical devices that comply with applicable standards of safety and effectiveness and other regulatory requirements. Home use devices are associated with unique risks created by the interactions among the user (often a layperson), the use environment, and the device. This document identifies several factors that manufacturers should consider, especially during device design and development, and provides recommendations for reducing or minimizing these unique risks. Comments are due by March 13, 2013. More information
Request for Comments:Impact of Approved Drug Labeling on Chronic Opioid Therapy
FDA invites comments on the public health benefits and risks, including the potential for abuse, of drugs containing hydrocodone either combined with other analgesics or as an antitussive. Over the past several years, the role of opioid drugs in treating chronic pain has been an increasingly common subject of public discussion. FDA and other policymakers have been at the forefront of these debates, striving to find a balance between minimizing opioid drug abuse and misuse, while simultaneously enabling appropriate access to pain-relieving drugs. Comments are due by April 8, 2013. More information
Drug Residue in our Food Supply
Illegal drug residues in the nation’s food supply are a concern to the Food and Drug Administration. The Center for Veterinary Medicine’s Division of Compliance is responsible for reviewing violative residues reported to the Agency by the USDA’s Food Safety and Inspection Service. The residues are ranked using a Risk Model to ensure Federal and/or State investigation of the residues of greatest public health concern for which assignments are issued. The Drug Residue Compliance Team provides regulatory support and outreach to prevent illegal drug residues by reviewing inspectional evidence sent to us by the FDA District Offices. More information
FDA Provides a Portal to India
The next time you stir black pepper, cumin, chili or cardamom into your stew, think about this: Nearly one quarter of the spices, oils and food colorings used in the United States comes from India. In fact, India is the largest producer, consumer and exporter of spices globally. But that’s not all. India is an important source of trade with the U.S. In 2011, India was the second largest drug exporter and the seventh largest food exporter to the U.S. The FDA works hard to make sure that these India-produced foods and drugs are safe, effective and of good quality. More information
FDA proposes new food safety standards for foodborne illness prevention and produce safety
The U.S. Food and Drug Administration today proposed two new food safety rules that will help prevent foodborne illness. The proposed rules implement the landmark, bipartisan FDA Food Safety Modernization Act (FSMA) and are available for public comment for the next 120 days. The FDA encourages Americans to review and comment on these important proposed rules. More information
New Drug Attacks Resistant TB by Margaret A. Hamburg, M.D., Commissioner of the U.S. Food and Drug Administration
Having seen first-hand the threat to public health posed by multi-drug resistant tuberculosis (MDR TB), which cannot be cured by many of the most powerful drugs usually used to treat the disease, I’m pleased that another weapon has been added to the arsenal for fighting this deadly, contagious disease. To continue reading this blog, see FDA Voice Blog, December 31, 2012.
FDA Commemorates 30th Anniversary of the Orphan Drug ActBy Gayatri R. Rao, M.D., J.D., Director for The Office of Orphan Products Development
When President Reagan signed the Orphan Drug Act 30 years ago, he enacted a critically important piece of health care legislation. The passage of this Act on January 4, 1983, was monumental because it created—for the first time—incentives to develop desperately needed medical products for Americans suffering with rare diseases. Until that point, development of such products was very limited. For instance, in the decade leading up to the passage of the Orphan Drug Act, only 10 industry-supported products for rare diseases were brought to market. To continue reading this blog, see FDA Voice Blog, January 7, 2013
Basing Food Safety Standards on Science and Prevention By Margaret Hamburg, M.D., Commissioner of the U.S. Food and Drug Administration
Two of my highest priorities as FDA commissioner have been strengthening the scientific foundation of FDA’s regulatory decisions and ensuring the safety of an increasingly complex and global food supply. That’s why I take such pride in FDA’s proposal of two rules that set science-based standards for the prevention of foodborne illnesses. One will govern facilities that produce food, and the other concerns the safety of produce. The Preventive Controls for Human Food rule proposes that food companies—whether they manufacture, process, pack or store food— put in place controls to minimize and reduce the risk of contamination. The Produce Safety rule proposes that farms that grow, harvest, pack or hold fruits and vegetables follow standards aimed at preventing their contamination. To continue reading this blog, see FDA Voice Blog, January 8, 2013
Cord Blood Banking – Information for Consumers
Expecting a baby can be a very exciting time for soon-to-be-parents. It can also be very confusing, with many decisions to make. One choice prospective parents often face is whether to donate, bank or discard their baby’s cord blood. Did you know that the Food and Drug Administration (FDA) regulates cord blood? Here is some information for expectant parents about the regulations in place designed to help ensure the safety of cord blood for transplantation. To continue reading this information for consumers
FDA advisory committee meetings are free and open to the public. No prior registration is required to attend. Interested persons may present data, information, or views, orally at the meeting, or in writing, on issues pending before the committee.
Other types of meetings listed may require prior registration and fees. Click on “More information” for details about each meeting.
Endocrinologic and Metabolic Drugs Advisory Committee Meeting
Date: January 10, 2013
The committee will discuss new drug application (NDA) 204042, canagliflozin tablets, proposed trade name INVOKANA, submitted by Janssen Research and Development, LLC. Canagliflozin is a member of the sodium-glucose co-transporter 2 (SGLT2) inhibitors, and was developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. More information
Cellular, Tissue and Gene Therapies Advisory Committee Meeting
Date: January 15, 2013
On January 15, 2013 from 2 p.m. to approximately 4:30 p.m., the Committee will meet, by teleconference, in open session, to hear updates on the research programs in the Laboratory of Immunology, Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA. From approximately 4:30 p.m. to 5:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of the intramural research programs and make recommendations regarding personnel staffing decisions. More information
Drug Safety and Risk Management Advisory Committee Meeting
Dates: January 24-25, 2013
The committee will discuss the public health benefits and risks, including the potential for abuse, of drugs containing hydrocodone either combined with other analgesics or as an antitussive. The Department of Health and Human Services received a request from the Drug Enforcement Administration for a scientific and medical evaluation and scheduling recommendation for these products in response to continued reports of misuse, abuse, and addiction related to these products. The committee will also discuss the impact of rescheduling these hydrocodone products from Schedule III to Schedule II. More information
Pulmonary-Allergy Drugs Advisory Committee Meeting
Date: January 29, 2013
The committee will discuss the new drug application (NDA) 203108, for olodaterol (proposed trade name Striverdi Respimat) metered dose inhaler, sponsored by Boehringer Ingelheim, for the proposed indication of long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. More information
Pulmonary-Allergy Drugs Advisory Committee Meeting
Date: January 30, 2013
The committee will discuss the new drug application (NDA) 202049, for mannitol inhalation powder (proposed trade name BRONCHITOL), for oral inhalation sponsored by Pharmaxis, for the proposed indication of management of cystic fibrosis (CF) in patients aged 6 years and older to improve pulmonary function. More information
Public Hearing: Impact of Approved Drug Labeling on Chronic Opioid Therapy
Dates: February 7-8, 2013
Over the past several years, the role of opioid drugs in treating chronic pain has been an increasingly common subject of public discussion. FDA and other policymakers have been at the forefront of these debates, striving to find a balance between minimizing opioid drug abuse and misuse, while simultaneously enabling appropriate access to pain-relieving drugs. The July 9, 2012, approval of the Risk Evaluation Management Strategy for extended-release (ER) and long-acting (LA) opioid analgesics is a recent example of FDA’s ongoing commitment to ensuring that the benefits of these types of opioid drugs continue to outweigh their risks. More information
Public Workshop: Clinical Development Programs for Disease-Modifying Agents for Peripheral Neuropathy
Dates: February 11-12, 2013
FDA is announcing this public workshop to further the understanding of the development of disease-modifying agents for the treatment of painful peripheral neuropathies. Discussion will focus on possible therapeutic targets for these agents, the types of painful peripheral neuropathies amenable to treatment with disease-modifying agents, and clinical trial design. More information
Risk Communication Advisory Committee Meeting
Date: February 12, 2013
The committee will discuss general factors in risk communication about FDA regulated products, including approaches to avoid message fatigue and related communication barriers such as prevention or warning fatigue or inaccurate risk perception. More information
Medical Imaging Drugs Advisory Committee Meeting
Date: February 14, 2013
The committee will discuss new drug application (NDA) 204781, proposed trade name DOTAREM (gadoterate meglumine injection), application submitted by Guerbet, LLC. The proposed indication (use) for this product is for magnetic resonance imaging in brain (intracranial), spine, and associated tissues in adults and pediatric patients (from neonates to 17 years of age) to detect and visualize areas with disruption of the blood brain barrier (specialized tissues that help protect the brain) and/or abnormal vascularity (abnormal blood circulation). More information
Neurological Devices Panel of the Medical Devices Advisory Committee Meeting
Date: February 22, 2013
The committee will discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) for the NeuroPace RNS System sponsored by NeuroPace, Inc. The RNS System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures from no more than two foci that are refractory to two or more antiepileptic medications. More information
Reproductive Health Drugs Advisory Committee Meeting
Date: March 4, 2013
The morning session, the committee will discuss new drug application (NDA) 022506, gabapentin 600 milligram (mg) tablets, submitted by Depomed, Inc., for the proposed indication of treatment of moderate to severe vasomotor symptoms due to menopause. During the afternoon session, the committee will discuss NDA 204516, paroxetine mesylate 7.5 mg capsules, submitted by Noven Therapeutics, LLC, for the proposed indication of treatment of moderate to severe vasomotor symptoms associated with menopause. More Information
Pulmonary-Allergy Drugs Advisory Committee Meeting
Date: March 7, 2013
The committee will discuss the new drug application (NDA) 204275 for fluticasone furoate and vilanterol dry powder inhaler (proposed tradename BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease. More information
Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee Meeting
Date: April 5, 2013
The committee will discuss and make recommendations regarding the possible reclassification of Shortwave Diathermy devices. On July 6, 2012 (77 FR 39953), FDA issued a proposed rule which, if made final, would make Shortwave Diathermy devices Class III, requiring premarket approval. In response to the proposed rule, FDA received petitions under section 515(b)(2)(B) of the Federal Food, Drug, and Cosmetic Act requesting a change in classification. The reclassification petitions are available for public review and comment at www.regulations.gov under docket number FDA-2012-N-0378.More information
Please visit FDA’s Advisory Committee page to obtain advisory committee meeting agendas, briefing materials, and meeting rosters prior to the meetings. You may also visit this page after meetings to obtain transcripts, presentations, and voting results. For additional information on other agency meetings please visit Meetings, Conferences, & Workshops.
Nutrition Facts Label: 20 and Evolving
When you’re walking down the aisles of a supermarket, it’s not unusual to see fellow shoppers reading the information on the back of a food package, box or can. They might want to know how many calories are in the food, or they might be watching their sodium intake.
They could be trying to limit sugars and eat more dietary fiber. Or they could be parents trying to make the most nutritious choices for their children.
All this information is available thanks to an important addition to food packaging that was introduced to the American public 20 years ago: the Nutrition Facts label. This familiar rectangular box provides, in a standard format, important information about the nutritional content for most packaged foods, including breads, cereals, canned and frozen foods, snacks, desserts and drinks. More information
FDA Strengthening our Food Safety Foundation
For the FDA, prevention is at the heart of food safety. “Preventing problems before they cause harm is not only common sense, it is the key to food safety in the 21st century,” says FDA Commissioner Margaret A. Hamburg, M.D. “We cannot afford to wait until people become ill to realize there is a problem.” Prevention is the core principle of the FDA Food Safety Modernization Act that President Obama signed into law in 2011, creating a blueprint for the most sweeping changes to the nation’s food protection system since Theodore Roosevelt held office. More information
Understanding Antidepressant Medications
Depression affects about 121 million people worldwide and is a leading cause of disability, according to the World Health Organization (WHO). “In my experience as a practicing psychiatrist, I’ve seen that many people with depression don’t realize that they have the condition or that it’s treatable,” says Mitchell Mathis, M.D., deputy director of the Division of Psychiatry Products at the FDA. Some who suffer from depression don’t recognize the symptoms, or they attribute them to lack of sleep or poor diet. More information
More Consumer Updates
For previously published Consumer Update articles that are Timely and easy-to-read and cover all FDA activities and regulated products. More information
Artículos en Español
Estos artículos para los consumidores incluyen información sobre la Administración de Medicamentos y Alimentos (FDA, Food and Drug Administration) y consejos para llevar una vida saludable. More information
Device Use Safety Tips
Medical Device Safety Tips highlight what can go wrong if labeling is overlooked or not followed, and provide advice on how to mitigate risks. More information
FDA Basics
Each month, different Centers and Offices at FDA will host an online session where the public can ask questions to senior FDA officials about a specific topic or just listen in to learn more about FDA. More information
Have a question about what the Center for Drug Evaluation and Research (CDER) does? Ask Janet Woodcock, M.D., Director, CDER, FDA
FDA will select some of your questions to answer each month. Due to the volume of e-mails we receive, we won’t be able to answer each question in this format. We may edit your questions for brevity or clarity. More information
Animal Health Literacy
Animal Health Literacy means timely information for the benefit of all animals and their humans. With continuous communication and outreach, the Center for Veterinary Medicine (CVM) strives to enhance the public trust, promote safe and effective use of the animal health products we regulate, and share our scientific endeavors. CVM provides reliable, science-based information to promote animal and human health. More information
CVM Pet Facts
The Center for Veterinary Medicine (CVM) issues medical and feeding fact sheets to keep your pets healthy and safe. More information
Center for Food Safety and Applied Nutrition
The Center for Food Safety and Applied Nutrition, known as CFSAN, carries out the mission of the Food and Drug Administration (FDA). The Center provides services to consumers, domestic and foreign industry and other outside groups regarding field programs; agency administrative tasks; scientific analysis and support; and policy, planning and handling of critical issues related to food and cosmetics. More information
Food Facts for You
The Center for Food Safety and Applied Nutrition, known as CFSAN, issues food fact for consumers to keep you and your family safe. More information
Tobacco Products Resources for You
Federal resources to help you quit using tobacco products and to help you learn more about youth tobacco prevention, effective treatment for nicotine addiction, and tobacco research and statistics. More information
COMMENT POLICY: We welcome comments from individuals and businesses. All comments are moderated. Comments are subject to rejection if they are vulgar, combative, or in poor taste.
REAL NAMES ONLY: All posters must use their real individual or business name. This applies equally to Twitter account holders who use a nickname.
The Los Angeles County Registrar-Recorder/County Clerk has reported that there are less than 20,000 ballots remaining to be counted in the Los Angeles County area.
Following an extensive search, the Governing Board of the William S. Hart Union High School District has unanimously selected current Interim Superintendent Dr. Michael Vierra as the new Hart District Superintendent, filling the vacancy created when Mike Kuhlman resigned effective June 30.
The nonprofit Raising the Curtain Foundation will host a fundraising event, "Holidayland" with mid-century pop culture expert Charles Phoenix, on Sunday, Dec. 8 at 3 p.m.
The Los Angeles County Registrar-Recorder/County Clerk has reported that there are less than 20,000 ballots remaining to be counted in the Los Angeles County area.
The Valley Industry Assoction will host a Cocktails & Conversation event with Cameron Smyth on Thursday, Dec. 12, 5:30=7:30 p.m. at Margarita’s Mexican Grill, 23320 Valencia Blvd., Valencia, CA 91355.
Following an extensive search, the Governing Board of the William S. Hart Union High School District has unanimously selected current Interim Superintendent Dr. Michael Vierra as the new Hart District Superintendent, filling the vacancy created when Mike Kuhlman resigned effective June 30.
"Christmas Carol: The True Meaning of Christmas" will be performed on stage at the Canyon Theatre Guild on weekends beginning Friday, Nov. 29 thru Monday, Dec. 23 at 24242 Main St., Newhall, CA 91321.
The California Air Resources Board has approved a $34.94 million incentives funding plan that will continue support ongoing efforts to increase access to medium- and heavy-duty zero-emission trucks, buses and equipment, with a focus on small businesses.
Preparing to decorate for the holidays? If you come across broken string lights that are no longer usable, instead of tossing in the trash you can now drop them off for recycling at one of the SAFE collection centers
The nonprofit Raising the Curtain Foundation will host a fundraising event, "Holidayland" with mid-century pop culture expert Charles Phoenix, on Sunday, Dec. 8 at 3 p.m.
The Santa Clarita City Council will hold its regular meeting Tuesday, Nov. 26, beginning with a special closed meeting at 5 p.m., followed immediately with open session at 6 p.m.
The American Cancer Society Relay for Life of Santa Clarita Valley will present its holiday boutique fundraiser, 10 a.m.-3 p.m. Saturday, Nov. 23, at Santa Clarita United Methodist Church, 26640 Bouquet Canyon Road, Santa Clarita, CA 91350.
California State Parks Office of Historic Preservation has announced it will begin accepting applications for the State Historic Rehabilitation Tax Credit Program at 8 a.m. on Jan. 6, 2025.
Due to construction and weather delays, the closure of the exercise staircase at Central Park, 27150 Bouquet Canyon Road, Santa Clarita, CA 91350, will be extended through Nov. 28.
Santa Clarita Ballet's 30th anniversary production of "The Nutcracker" will perform, Saturday and Sunday, Dec. 14-15 at the Santa Clarita Performing Arts Center, 26455 Rockwell Canyon Road, Santa Clarita, CA 91355.
Theatre in a Week and Off Book Theatre is back with its holiday one act comedy "Holiday Hijinx" Friday, Dec. 13- Sunday, Dec. 15 at The MAIN in Old Town Newhall.
The Santa Clarita Master Chorale presents its Silver Bell Jubilee concert Sunday, Dec. 8, 4 p.m. at Santa Clarita Performing Arts Center, 26455 Rockwell Canyon Road, Santa Clarita, CA 91355.
Celebrate this special time of year with the 29th annual Winter Magic Lighted Boat Parade and holiday event Saturday, Dec. 7 at Castaic Lake, Lower Lagoon.
1967 - Local voters approve formation of community college and elect COC's first five-member board - Dr. William G. Bonelli Jr., Bruce Fortine, Sheila Dyer, Peter Huntsinger, Edward Muhl [story]
You can make a difference in a child or teen’s life this holiday season through the Boys and Girls Club of the Santa Clarita Valley. You can volunteer at a club holiday event, host a toy drive, sponsor a club family or make a donation.
Tweet This
Facebook
Digg This
Bookmark
Stumble
RSS
Fisher and Paykel Healthcare Reusable Breathing Circuit: Class I Recall – Pinholes in Tubes
Medication Guides for Certain Prescription Medicines
Comunicaciones de la FDA sobre la seguridad de los medicamentos en español
FDA recognizes the significant public health consequences that can result from drug shortages and takes tremendous efforts within its legal authority to address and prevent drug shortages. These shortages occur for many reasons, including manufacturing and quality problems, delays, and discontinuations. When quality/manufacturing and quality problems, delays, and discontinuations. When quality/manufacturing issues are discovered by the company or the public and reported to FDA or are found by FDA upon inspection, the FDA works closely with the firm to address risks involved to prevent harm to patients. FDA also considers the impact a shortage would have on patient care and access and works with the firm to restore supplies while also ensuring safety for patients.
Sirturo approved to treat multi-drug resistant pulmonary tuberculosis
Guidance Documents on MDUFA III
Request for Comments: Information To Accompany Humanitarian Device Exemption Applications and Annual Distribution Number Reporting Requirements
Drug Residue in our Food Supply
FDA proposes new food safety standards for foodborne illness prevention and produce safety
Endocrinologic and Metabolic Drugs Advisory Committee Meeting
Pulmonary-Allergy Drugs Advisory Committee Meeting
Medical Imaging Drugs Advisory Committee Meeting
Nutrition Facts Label: 20 and Evolving
FDA Strengthening our Food Safety Foundation
Have a question about what the Center for Drug Evaluation and Research (CDER) does? Ask Janet Woodcock, M.D., Director, CDER, FDA
Center for Food Safety and Applied Nutrition
Tobacco Products Resources for You
REAL NAMES ONLY: All posters must use their real individual or business name. This applies equally to Twitter account holders who use a nickname.
0 Comments
You can be the first one to leave a comment.